Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 3/20 | 0.47 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.47 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10094631 | 0.87 | HSD11B1 (0.46) | HSD11B1PIK3CAMTORAVPR1ATRPV1 | |
| SCHEMBL1370146 | 0.83 | LMNA (0.59) | HSD11B1PARP1TNK2TNK1TRPV1 | |
| SCHEMBL3435691 | 0.82 | GRIN2D (0.54) | PIK3CAMTORTRPV1LMNAEPHX2 | |
| SCHEMBL615931 | 0.81 | EPHX2 (0.59) | HSD11B1EPHX2 | |
| Hydrochloric Acid SCHEMBL23124285 | 0.80 | EPHX2 (0.58) | HSD11B1EPHX2 | |
| Hydrochloric Acid SCHEMBL20339507 | 0.80 | EPHX2 (0.58) | HSD11B1EPHX2 | |
| Hydrochloric Acid SCHEMBL10317373 | 0.80 | EPHX2 (0.58) | HSD11B1EPHX2 | |
| SCHEMBL3434185 | 0.78 | LMNA (0.73) | HSD11B1LMNA | |
| SCHEMBL3436625 | 0.77 | ADRB1 (0.62) | AVPR1ALMNA | |
| SCHEMBL14818765 | 0.76 | EPHX2 (0.54) | HSD11B1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | HSD11B1 3972/4885PARP1 3052/4885TNK2 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.